Nascent Biotech, Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported net loss was USD 2.09 million compared to USD 2.8 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.085 USD | 0.00% |
|
-4.39% | -50.84% |
07-01 | Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
04-16 | Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run | CI |
1st Jan change | Capi. | |
---|---|---|
-50.84% | 14.64M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.6B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024